image
Alexander's, Inc. ALX
Real Estate - REIT - Retail - NYSE - US
Watchlist
$ 232.52
0.702 %
$ 1.19 B
Market Cap
30.12
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one ALX stock under the worst case scenario is HIDDEN Compared to the current market price of 233 USD, Alexander's, Inc. is HIDDEN

ALX Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one ALX stock under the base case scenario is HIDDEN Compared to the current market price of 233 USD, Alexander's, Inc. is HIDDEN

ALX Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one ALX stock under the best case scenario is HIDDEN Compared to the current market price of 233 USD, Alexander's, Inc. is HIDDEN

ALX Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart ALX

image
1M 1%
6M 22%
1Y 13%
3Y 30%
5Y 45%
All
$240.0$240.0$230.0$230.0$220.0$220.0$210.0$210.0$200.0$200.0$190.0$190.0$180.0$180.0$170.0$170.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
226 M REVENUE
0.63%
Growth Rates
1Year 0.63%
3Years 3.17%
5Years 0.00%
7Years -0.26%
10Years 1.21%
117 M OPERATING INCOME
-0.68%
Growth Rates
1Year -0.68%
3Years 2.23%
5Years 3.23%
7Years 1.47%
10Years 1.89%
43.4 M NET INCOME
-57.58%
Growth Rates
1Year -57.58%
3Years -31.12%
5Years -6.28%
7Years -8.44%
10Years -4.37%
54.1 M OPERATING CASH FLOW
-50.41%
Growth Rates
1Year -50.41%
3Years -22.99%
5Years -15.56%
7Years -11.11%
10Years 0.90%
-13.2 M INVESTING CASH FLOW
-4.11%
Growth Rates
1Year -4.11%
3Years -5.53%
5Years -6.95%
7Years 32.26%
10Years 16.63%
-200 M FINANCING CASH FLOW
-116.42%
Growth Rates
1Year -116.42%
3Years -7.66%
5Years -16.77%
7Years -17.32%
10Years -8.57%
54.9 M REVENUE
-1.78%
Growth Rates
1Year 0.63%
3Years 3.17%
5Years 0.00%
7Years -0.26%
10Years 1.21%
19.2 M OPERATING INCOME
-0.58%
Growth Rates
1Year -0.68%
3Years 2.23%
5Years 3.23%
7Years 1.47%
10Years 1.89%
12.3 M NET INCOME
0.29%
Growth Rates
1Year -57.58%
3Years -31.12%
5Years -6.28%
7Years -8.44%
10Years -4.37%
2.02 M OPERATING CASH FLOW
-93.43%
Growth Rates
1Year -50.41%
3Years -22.99%
5Years -15.56%
7Years -11.11%
10Years 0.90%
-8.02 M INVESTING CASH FLOW
19.38%
Growth Rates
1Year -4.11%
3Years -5.53%
5Years -6.95%
7Years 32.26%
10Years 16.63%
-23.9 M FINANCING CASH FLOW
1.29%
Growth Rates
1Year -116.42%
3Years -7.66%
5Years -16.77%
7Years -17.32%
10Years -8.57%
Balance Sheet Alexander's, Inc.
image
Current Assets 511 M
Cash & Short-Term Investments 339 M
Receivables 117 M
Other Current Assets 55.3 M
Non-Current Assets 831 M
Long-Term Investments 0
PP&E 0
Other Non-Current Assets 831 M
25.24 %8.71 %4.12 %61.93 %Total Assets$1.3b
Current Liabilities 39.9 M
Accounts Payable 38.7 M
Short-Term Debt 0
Other Current Liabilities 1.16 M
Non-Current Liabilities 1.12 B
Long-Term Debt 1.1 B
Other Non-Current Liabilities 21.4 M
3.33 %94.74 %Total Liabilities$1.2b
EFFICIENCY
Earnings Waterfall Alexander's, Inc.
image
Revenue 226 M
Cost Of Revenue 103 M
Gross Profit 85.9 M
Operating Expenses 6.52 M
Operating Income 117 M
Other Expenses 73.2 M
Net Income 43.4 M
250m250m200m200m150m150m100m100m50m50m00226m(103m)86m(7m)117m(73m)43mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
37.95% GROSS MARGIN
37.95%
Averages
1Year 37.95%
3Years 49.67%
5Years 58.87%
7Years 59.21%
10Years 60.46%
36.15% OPERATING MARGIN
36.15%
Averages
1Year 36.15%
3Years 43.41%
5Years 41.01%
7Years 42.27%
10Years 43.38%
19.19% NET MARGIN
19.19%
Averages
1Year 19.19%
3Years 26.27%
5Years 30.44%
7Years 25.10%
10Years 28.57%
24.56% ROE
24.56%
Averages
1Year 24.56%
3Years 26.64%
5Years 28.26%
7Years 23.02%
10Years 23.09%
3.24% ROA
3.24%
Averages
1Year 3.24%
3Years 4.20%
5Years 4.68%
7Years 3.90%
10Years 4.35%
6.29% ROIC
6.29%
Averages
1Year 6.29%
3Years 6.06%
5Years 5.09%
7Years 5.07%
10Years 5.64%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Alexander's, Inc.
image
140m140m120m120m100m100m80m80m60m60m40m40m20m20m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 43.4 M
Depreciation & Amortization 37.9 M
Capital Expenditures 0
Stock-Based Compensation 450 K
Change in Working Capital -47.8 M
Others -14 M
Free Cash Flow 54.1 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Alexander's, Inc.
image
Wall Street analysts predict an average 1-year price target for ALX of $125 , with forecasts ranging from a low of $125 to a high of $125 .
ALX Lowest Price Target Wall Street Target
125 USD -46.24%
ALX Average Price Target Wall Street Target
125 USD -46.24%
ALX Highest Price Target Wall Street Target
125 USD -46.24%
Price
Max Price Target
Min Price Target
Average Price Target
240240220220200200180180160160140140120120Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
2.15% DIVIDEND YIELD
4.5 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
20.0020.0018.0018.0016.0016.0014.0014.0012.0012.0010.0010.008.008.006.006.004.004.002.002.000.000.003.544.254.54.54.54.54.54.54.54.53.544.254.54.54.54.54.54.54.54.53.544.254.54.54.54.54.54.54.53.514.00416.004.2517.004.518.004.518.004.518.004.518.004.518.004.518.004.518.009.002015201520162016201720172018201820192019202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 6
6. Ownership
Insider Ownership Alexander's, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
5 Office REITs For The Great Return To Office “Programmer.” forbes.com - 1 week ago
Are Finance Stocks Lagging Alexander's (ALX) This Year? Here is how Alexander's (ALX) and Axa Sa (AXAHY) have performed compared to their sector so far this year. zacks.com - 1 week ago
Is Alexander's (ALX) Stock Outpacing Its Finance Peers This Year? Here is how Alexander's (ALX) and Balfour Beatty PLC Sponsored ADR (BLFBY) have performed compared to their sector so far this year. zacks.com - 3 weeks ago
Best Income Stocks to Buy for June 2nd ALX, HMN and EBC made it to the Zacks Rank #1 (Strong Buy) income stocks list on June 2, 2025. zacks.com - 1 month ago
Best Momentum Stock to Buy for June 2nd WTKWY and ALX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 2, 2025. zacks.com - 1 month ago
ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that management will participate in the Jefferies 2025 Global Healthcare Conference. Details are as follows: globenewswire.com - 1 month ago
Best Momentum Stock to Buy for May 29th ALX and WTKWY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 29, 2025. zacks.com - 1 month ago
Best Income Stocks to Buy for May 29th ALX, ISNPY and EBC made it to the Zacks Rank #1 (Strong Buy) income stocks list on May 29, 2025. zacks.com - 1 month ago
New Strong Buy Stocks for May 29th ALX, SPFI, BWB, NIC and WTKWY have been added to the Zacks Rank #1 (Strong Buy) List on May 29, 2025. zacks.com - 1 month ago
Are Finance Stocks Lagging Alexander's (ALX) This Year? Here is how Alexander's (ALX) and Berkeley Group Holdings PLC Unsponsored ADR (BKGFY) have performed compared to their sector so far this year. zacks.com - 1 month ago
ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event - A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic window by reducing toxicity globenewswire.com - 1 month ago
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025 SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that it will host a webcast event on May 20, 2025, to provide an update on ALX2004, the Company's potentially best- and first-in-class investigational antibody-drug conjugate (ADC). The webcast will highlight the novel mechanism of action, preclinical data and clinical development strategy for ALX2004 following clearance of the Investigational New Drug application from the U.S. Food and Drug Administration earlier this year. globenewswire.com - 1 month ago
8. Profile Summary

Alexander's, Inc. ALX

image
COUNTRY US
INDUSTRY REIT - Retail
MARKET CAP $ 1.19 B
Dividend Yield 2.15%
Description Alexander's, Inc. is a real estate investment trust which has seven properties in the greater New York City metropolitan area.
Contact 210 Route 4 East, Paramus, NJ, 07652 https://www.alx-inc.com
IPO Date Feb. 21, 1973
Employees 90
Officers Mr. Steven Roth Chairman of the Board & Chief Executive Officer Mr. Steven J. Borenstein Secretary Mr. Gary W. Hansen Chief Financial Officer